Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

BG Medicine acquires exclusive commercial rights to vascular plaque rupture biomarker

BG Medicine : 07 February, 2008  (New Product)
BG Medicine and ACS Biomarker have entered into an agreement in which BG Medicine has obtained rights to develop and commercialise a novel clinical diagnostic test for acute atherothrombosis based on a biomarker discovered by the Cardiovascular Research Institute Maastricht (CARIM).
ACS Biomarker has granted BG Medicine exclusive, worldwide commercial rights to pursue the development, validation, regulatory approval and commercialisation of diagnostic tests based on the Biomarker discovered by CARIM, in exchange for milestone payments, royalties based on net sales and sublicensing income of any products commercialised under the license.

Atherothrombosis occurs when vascular plaque ruptures leading to thrombosis, or clotting, in the affected artery, which in turn can progress to life-threatening conditions such as heart attacks and stroke. The underlying condition is usually asymptomatic until the presentation of a serious or life-threatening event, resulting from the rupture.

The novel test that BG Medicine expects to develop aims to use the Biomarker discovered by CARIM to identify plaque rupture in patients early, for instance, when the blockage is temporary or not complete and has not yet caused the common signs and symptoms of heart attack or stroke.

Specifically, the test aims to aid in the diagnosis of less severe or transient conditions such as Transient Ischemic Attacks (TIAs), cerebrovascular disorders that are often considered ‘warning-strokes’ which produce stroke-like symptoms, and unstable angina, which is the sudden increase of blockage in a coronary artery caused by a blood clot. These conditions are often precursors to heart attacks, strokes or other major cardiac events. For example, a TIA is followed by a stroke in 10 percent of patients within 90 days after the TIA. The test may also provide reliable data in the early hours following a heart attack when current tests are not reliable.

ACS Biomarker, a company that was formed with technology exclusively licensed from the University of Maastricht and other parties, was founded to develop and commercialise cardiovascular biomarkers discovered at CARIM. The Biomarker licensed to BG Medicine from ACS Biomarker was discovered by Professor Mat Daemen, who is one of the founders of ACS Biomarker and scientific director of CARIM.

This is the second agreement between BG Medicine and ACS Biomarker. In May 2007, BG Medicine acquired the exclusive rights to develop and commercialise diagnostic tests for congestive heart failure based on certain, other biomarkers that it licensed from ACS Biomarker.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 ProHealthServiceZone.com
Netgains Logo